Project Grant HT94252411090
Award Date
9/30/24
Completion Date
9/29/28
Dollars Obligated
$4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $4,523,000.00 to the University of Maryland, Baltimore to conduct a first-in-human Phase 1 clinical trial using trispecific (CD19/CD20/CD22) CAR T cells for the treatment of relapsed/refractory B cell lymphoma. The award period runs from September 30, 2025 to September 29, 2029. This research aims to transform healthcare for military service members,...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...
The U.S. Defense Health Agency awarded a $559,992 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The grant supports the "Bench-to-Bedside Development of Superior CAR T-Cell Therapy for Leukemia" research project, which aims to transform healthcare for military service members, veterans, and the public through innovative biomedical research. The project will run from September 30, 2025 to September 29, 2028,...
The project grant award of $880,000 is funded by the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant is awarded to the Sloan-Kettering Institute for Cancer Research to conduct research on using interferon E as a tumor suppressor and potential therapeutic for pancreatic cancer. The project will take place over a 3-year period from September 1, 2024 to August 31, 2027. As a leading comprehensive cancer...
The Defense Health Agency awarded a $1,108,654 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 30, 2025, will fund research to accelerate global research for relapsed or refractory extracranial malignant germ cell tumors. The Sloan-Kettering Institute, a leading nonprofit cancer research institution, will leverage its extensive capabilities in cancer biology, genomics,...
The Defense Health Agency awarded a $923,805 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research in New York. The grant supports a 3-year research project titled "Systematic Functional Dissection of Cancer Cell States in Lung Tumors" starting September 1, 2025. The grant aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the broader...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $778,092.00 to the Dana-Farber Cancer Institute, Inc. (Dfci) to advance preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. The award, effective from April 15, 2025 to April 14, 2027, supports Dfci's research focused on developing innovative CAR-T cell therapies to achieve...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC). The research will involve experimental design and computational analysis of...